Developer docs
API playgroundTry for free, no card

Search company profiles

Mirum Pharmaceuticals

Full company profile

uuid0000sgv

Namestring
Mirum Pharmaceuticals
Legal namestring
Mirum Pharmaceuticals, Inc.
Websiteurl
mirumpharma.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused exclusively on rare diseases, primarily in hepatology and adjacent ultra-rare genetic conditions. Founded in 2018 and headquartered in Foster City, California, the company has built a portfolio of three FDA-approved medicines (LIVMARLI/maralixibat, CHOLBAM/cholic acid, and CTEXLI/chenodiol) targeting cholestatic liver diseases such as Alagille syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC), bile acid synthesis disorders, peroxisomal disorders, and cerebrotendinous xanthomatosis. Mirum's underlying technology centers on ileal bile acid transporter (IBAT) inhibition, monoclonal antibodies, and small-molecule inhibitors of ALK2 and PDE4D, applied to conditions with profound disease burden and no approved alternatives.

The company generates revenue primarily through direct sales of approved medicines, distributed through specialty pharmacy channels in the United States and Canada and through wholly-owned subsidiary offices across Germany, France, Italy, Switzerland, Belgium, the Netherlands, and Austria, with Japan commercialization handled by Takeda. LIVMARLI, an oral IBAT inhibitor available in both liquid and tablet formulations, is the flagship product and the primary revenue driver, with sales reaching $359 million in 2025 (+69% YoY) across 30+ countries. Pricing is managed through specialty pharmacy and patient support programs (Mirum Access Plus), with detailed list pricing not publicly disclosed.

Mirum's growth strategy combines organic label expansions with inorganic deal-making. The January 2026 acquisition of Bluejay Therapeutics added brelovitug, a Breakthrough-Therapy-designated monoclonal antibody for chronic hepatitis delta virus, and the April 2026 exclusive license of zilurgisertib from Incyte brought in an oral ALK2 inhibitor for fibrodysplasia ossificans progressiva with a September 26, 2026 PDUFA date. The company supports its portfolio with a deep medical affairs footprint, extensive patient advocacy partnerships, and a proprietary Scout by Mirum diagnostic testing program that helps identify patients with rare genetic conditions. As of mid-2026, Mirum trades on NASDAQ under MIRM, employs 251-500 staff, and has a market capitalization approaching $7.6 billion following 147% trailing stock appreciation.

Short descriptiontext

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare liver and genetic diseases, serving patients with conditions like Alagille syndrome, PFIC, and hepatitis delta across 30+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersFoster City, United States
HQ citystring
Foster City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, specialty pharmaceuticals, cholestatic liver treatments, monoclonal antibody therapies, bile acid modulators
Industry4 codes
PRIMARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1LIVMARLI (maralixibat) sales
TypeOne Time License
Description

LIVMARLI is the flagship product generating $359 million in 2025 sales (up 69% YoY). Sold in both liquid and tablet formulations for Alagille syndrome and PFIC across U.S., EU, Canada and 30+ countries globally. Revenue from direct commercial sales.

finance.yahoo.com
2CHOLBAM/CTEXLI (bile acid medicines)
TypeOne Time License
Description

CHOLBAM (cholic acid) and CTEXLI (chenodiol) generated $161 million in 2025 sales (up 31% YoY). CHOLBAM treats bile acid synthesis disorders and peroxisomal disorders; CTEXLI treats cerebrotendinous xanthomatosis (CTX).

finance.yahoo.com
3Pipeline development and potential future product launches
TypeSubscription Recurring
Description

Mirum expects multiple product launches 2027-2028 including volixibat for PSC/PBC, brelovitug for HDV, and zilurgisertib for FOP, representing future revenue streams from current late-stage pipeline assets.

pharmiweb.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SCOUT by Mirum
Description

Diagnostic testing program partnering with laboratories to offer free testing kits for rare disease diagnosis

mirumpharma.com
+2 more records
Core offering1 text field

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases, primarily cholestatic liver diseases and other ultra-rare conditions. The company markets three FDA-approved medicines — LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CTEXLI (chenodiol) — and has a pipeline of investigational therapies including volixibat, brelovitug, zilurgisertib, and MRM-3379 targeting high-unmet-need patient populations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • LIVMARLI achieved $359 million in 2025 sales, up 69% year-over-year
+3 more records
Product overview1 text field

Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, with three FDA-approved medicines and multiple investigational therapies in its pipeline. The approved portfolio includes LIVMARLI (maralixibat) for Alagille syndrome and PFIC, CHOLBAM (cholic acid) for bile acid synthesis disorders, and CTEXLI (chenodiol) for Cerebrotendinous Xanthomatosis. The pipeline includes volixibat for PSC and PBC, brelovitug for hepatitis delta virus, zilurgisertib for fibrodysplasia ossificans progressiva, and MRM-3379 for Fragile X Syndrome. The company operates as a biopharmaceutical commercialization and development organization rather than a technology platform.

Product and service7 records
1LIVMARLI (maralixibat)
CategoryApproved drug product
Description

An orally administered ileal bile acid transporter (IBAT) inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older, and in patients with Progressive Familial Intrahepatic Cholestasis (PFIC) 12 months of age and older. Available in both liquid and tablet formulations.

2CHOLBAM (cholic acid)
CategoryApproved drug product
Description

A bile acid replacement therapy approved for treatment of bile acid synthesis disorders due to single enzyme deficiencies, and for treatment of peroxisomal disorders including Zellweger spectrum disorders in patients showing signs of liver disease.

3CTEXLI (chenodiol)
CategoryApproved drug product
Description

A bile acid therapy approved by the FDA for treatment of adults with Cerebrotendinous Xanthomatosis (CTX). It is the first and only treatment designed to reduce overproduction of toxic bile acid precursors.

4Volixibat
CategoryInvestigational drug product
Description

A minimally absorbed, orally administered investigational therapy designed to selectively inhibit IBAT for treatment of cholestatic pruritus associated with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Has received FDA Breakthrough Therapy designation for PBC.

5Brelovitug
CategoryInvestigational drug product
Description

An investigational fully human monoclonal antibody being studied for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis. Has received FDA Breakthrough Therapy designation and EMA PRIME designation for HDV.

6Zilurgisertib
CategoryInvestigational drug product
Description

An investigational oral small-molecule therapy designed to selectively inhibit ALK2 (ACVR1) for treatment of fibrodysplasia ossificans progressiva (FOP). Licensed from Incyte for worldwide development and commercialization.

7MRM-3379
CategoryInvestigational drug product
Description

An allosteric inhibitor of phosphodiesterase-4D (PDE4D) being studied for treatment of Fragile X Syndrome (FXS). Licensed from Enthorin Therapeutics.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

In April 2026, Mirum entered into an exclusive license agreement with Incyte for worldwide rights to zilurgisertib, an oral ALK2 inhibitor for fibrodysplasia ossificans progressiva. Mirum acquired the asset for $16 million upfront plus up to $63 million in milestones. Companies jointly announced positive Phase 2 PROGRESS study data in June 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

Mirum completed acquisition of Bluejay Therapeutics in January 2026 for $620 million in cash and stock plus up to $200 million in potential milestone payments. Acquired worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus with FDA Breakthrough Therapy designation.

Strategic tierMinorTypeOthersAnnounced on2025-12-01
Description

Davis Polk advised Mirum on $200 million private placement of common stock and pre-funded warrants to fund clinical development and pipeline expansion.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Takeda serves as commercial partner for LIVMARLI in Japan, handling regulatory approvals and commercialization. LIVMARLI was approved in Japan through partner Takeda for PFIC and Alagille syndrome.

5Enthorin Therapeutics
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-01
Description

Mirum licensed MRM-3379 (formerly ENT-3379), an orally available selective PDE4D inhibitor for Fragile X syndrome, from Enthorin Therapeutics. Mirum initiated BLOOM Phase 2 clinical study in December 2025.

mirumpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership through Scout by Mirum program providing free genetic testing kits including 143-gene cholestasis panel, 66-gene early-onset bilateral cataracts panel, and PBD-ZSD testing.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership through Scout by Mirum program providing mass spectrometry testing for bile acid synthesis disorders and peroxisomal disorders at no cost to patients.

8Oregon Health & Science University
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership through Scout by Mirum program for cerebrotendinous xanthomatosis (CTX) testing through OHSU Sterol Analysis Clinical Laboratory.

mirumpharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership through Scout by Mirum program for Smith-Lemli-Opitz syndrome (SLOS) testing providing biochemical test for cholesterol and 7/8-DHC intermediates.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established rare-disease unit of AstraZeneca with multiple approved rare-disease therapies and global commercial reach. Comparable in commercial rare-disease infrastructure and orphan-drug pricing model.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company focused on rare genetic diseases with multiple approved RNAi therapeutics. Comparable in scale, rare-disease focus, and reliance on specialty distribution and orphan-drug pricing economics.

TypeDirect peer
Description

Established rare-disease biopharma with a multi-product commercial portfolio of orphan drugs across multiple therapeutic areas. Most directly comparable to Mirum in business model: a focused rare-disease commercial engine with ongoing pipeline replenishment.

TypeEmerging player
Description

Liver-focused biopharma commercializing obeticholic acid for PBC. Comparable therapeutic focus on rare cholestatic liver disease and similar commercial model targeting hepatologists, though now under Alfasigma ownership.

TypeEmerging player
Description

Commercial-stage rare disease biotech with focused launches in ultra-rare oncology and rare disorders. Comparable in company stage, rare-disease commercial motion, and reliance on single-asset growth narratives.

TypeDirect peer
Description

Specialty pharma division focused on rare diseases with global commercialization infrastructure. Comparable in rare-disease commercial model and emphasis on smaller patient populations with high unmet need.

TypeBroad incumbent
Description

Global biopharma with a large rare disease franchise (post-Shire acquisition) and existing commercial partnership with Mirum in Japan. Operates broadly in rare GI/liver diseases; comparable in therapeutic area but at vastly greater scale.

TypeEmerging player
Description

Late-stage biotech focused on cholestatic and metabolic liver diseases, including PBC. Direct overlap with Mirum's volixibat program in primary biliary cholangitis — a head-to-head competitive threat in the IBAT/PBC space.

TypeDirect peer
Description

Rare and ultra-rare disease biotech with multiple approved products and a similar specialty distribution model. Overlapping customer base (specialty prescribers, rare disease advocacy) and similar pipeline-driven growth narrative.

TypeBroad incumbent
Description

Global specialty pharma with strong rare disease and hepatic portfolios. Overlaps with Mirum in liver and rare disease therapy categories but operates at meaningfully greater scale and portfolio breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mirum Pharmaceuticals

Rare Disease Biopharmaceuticalsmirumpharma.com

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare liver and genetic diseases, serving patients with conditions like Alagille syndrome, PFIC, and hepatitis delta across 30+ countries.

What Mirum Pharmaceuticals does

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused exclusively on rare diseases, primarily in hepatology and adjacent ultra-rare genetic conditions. Founded in 2018 and headquartered in Foster City, California, the company has built a portfolio of three FDA-approved medicines (LIVMARLI/maralixibat, CHOLBAM/cholic acid, and CTEXLI/chenodiol) targeting cholestatic liver diseases such as Alagille syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC), bile acid synthesis disorders, peroxisomal disorders, and cerebrotendinous xanthomatosis. Mirum's underlying technology centers on ileal bile acid transporter (IBAT) inhibition, monoclonal antibodies, and small-molecule inhibitors of ALK2 and PDE4D, applied to conditions with profound disease burden and no approved alternatives.

The company generates revenue primarily through direct sales of approved medicines, distributed through specialty pharmacy channels in the United States and Canada and through wholly-owned subsidiary offices across Germany, France, Italy, Switzerland, Belgium, the Netherlands, and Austria, with Japan commercialization handled by Takeda. LIVMARLI, an oral IBAT inhibitor available in both liquid and tablet formulations, is the flagship product and the primary revenue driver, with sales reaching $359 million in 2025 (+69% YoY) across 30+ countries. Pricing is managed through specialty pharmacy and patient support programs (Mirum Access Plus), with detailed list pricing not publicly disclosed.

Mirum's growth strategy combines organic label expansions with inorganic deal-making. The January 2026 acquisition of Bluejay Therapeutics added brelovitug, a Breakthrough-Therapy-designated monoclonal antibody for chronic hepatitis delta virus, and the April 2026 exclusive license of zilurgisertib from Incyte brought in an oral ALK2 inhibitor for fibrodysplasia ossificans progressiva with a September 26, 2026 PDUFA date. The company supports its portfolio with a deep medical affairs footprint, extensive patient advocacy partnerships, and a proprietary Scout by Mirum diagnostic testing program that helps identify patients with rare genetic conditions. As of mid-2026, Mirum trades on NASDAQ under MIRM, employs 251-500 staff, and has a market capitalization approaching $7.6 billion following 147% trailing stock appreciation.

Mirum Pharmaceuticals firmographics

Firmographics
Name
Mirum Pharmaceuticals
Legal name
Mirum Pharmaceuticals, Inc.
Website
https://mirumpharma.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare liver and genetic diseases, serving patients with conditions like Alagille syndrome, PFIC, and hepatitis delta across 30+ countries.
Ownership category
akta.pro rank

Mirum Pharmaceuticals industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Rare disease therapeutics
  • Specialty pharmaceuticals
  • Cholestatic liver treatments
  • Monoclonal antibody therapies
  • Bile acid modulators

Where Mirum Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Foster City
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Mirum Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. LIVMARLI (maralixibat) sales: LIVMARLI is the flagship product generating $359 million in 2025 sales (up 69% YoY). Sold in both liquid and tablet formulations for Alagille syndrome and PFIC across U.S., EU, Canada and 30+ countries globally. Revenue from direct commercial sales.
  2. CHOLBAM/CTEXLI (bile acid medicines): CHOLBAM (cholic acid) and CTEXLI (chenodiol) generated $161 million in 2025 sales (up 31% YoY). CHOLBAM treats bile acid synthesis disorders and peroxisomal disorders; CTEXLI treats cerebrotendinous xanthomatosis (CTX).
  3. Pipeline development and potential future product launches: Mirum expects multiple product launches 2027-2028 including volixibat for PSC/PBC, brelovitug for HDV, and zilurgisertib for FOP, representing future revenue streams from current late-stage pipeline assets.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Mirum Pharmaceuticals product offering

Product offering

Core offering

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases, primarily cholestatic liver diseases and other ultra-rare conditions. The company markets three FDA-approved medicines — LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CTEXLI (chenodiol) — and has a pipeline of investigational therapies including volixibat, brelovitug, zilurgisertib, and MRM-3379 targeting high-unmet-need patient populations.

Product overview

Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, with three FDA-approved medicines and multiple investigational therapies in its pipeline. The approved portfolio includes LIVMARLI (maralixibat) for Alagille syndrome and PFIC, CHOLBAM (cholic acid) for bile acid synthesis disorders, and CTEXLI (chenodiol) for Cerebrotendinous Xanthomatosis. The pipeline includes volixibat for PSC and PBC, brelovitug for hepatitis delta virus, zilurgisertib for fibrodysplasia ossificans progressiva, and MRM-3379 for Fragile X Syndrome. The company operates as a biopharmaceutical commercialization and development organization rather than a technology platform.

Differentiator

Problem solved

Functional benefit

Brands

  • SCOUT by Mirum: Diagnostic testing program partnering with laboratories to offer free testing kits for rare disease diagnosis
  • Mirum Access Plus (MAP)
  • Embrace Patient Support Program

Products and services

  • LIVMARLI (maralixibat) An orally administered ileal bile acid transporter (IBAT) inhibitor approved for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older, and in patients with Progressive Familial Intrahepatic Cholestasis (PFIC) 12 months of age and older. Available in both liquid and tablet formulations.
  • CHOLBAM (cholic acid) A bile acid replacement therapy approved for treatment of bile acid synthesis disorders due to single enzyme deficiencies, and for treatment of peroxisomal disorders including Zellweger spectrum disorders in patients showing signs of liver disease.
  • CTEXLI (chenodiol) A bile acid therapy approved by the FDA for treatment of adults with Cerebrotendinous Xanthomatosis (CTX). It is the first and only treatment designed to reduce overproduction of toxic bile acid precursors.
  • Volixibat A minimally absorbed, orally administered investigational therapy designed to selectively inhibit IBAT for treatment of cholestatic pruritus associated with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Has received FDA Breakthrough Therapy designation for PBC.
  • Brelovitug An investigational fully human monoclonal antibody being studied for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis. Has received FDA Breakthrough Therapy designation and EMA PRIME designation for HDV.
  • Zilurgisertib An investigational oral small-molecule therapy designed to selectively inhibit ALK2 (ACVR1) for treatment of fibrodysplasia ossificans progressiva (FOP). Licensed from Incyte for worldwide development and commercialization.
  • MRM-3379 An allosteric inhibitor of phosphodiesterase-4D (PDE4D) being studied for treatment of Fragile X Syndrome (FXS). Licensed from Enthorin Therapeutics.

Quantifiable outcome

  • LIVMARLI achieved $359 million in 2025 sales, up 69% year-over-year
  • +3 more outcomes

Companies that use Mirum Pharmaceuticals

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Mirum Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Mirum Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • IncytecoreStrategic or Co-development Partner · 1 April 2026In April 2026, Mirum entered into an exclusive license agreement with Incyte for worldwide rights to zilurgisertib, an oral ALK2 inhibitor for fibrodysplasia ossificans progressiva. Mirum acquired the asset for $16 million upfront plus up to $63 million in milestones. Companies jointly announced positive Phase 2 PROGRESS study data in June 2026.
  • Bluejay TherapeuticscoreStrategic or Co-development Partner · 26 January 2026Mirum completed acquisition of Bluejay Therapeutics in January 2026 for $620 million in cash and stock plus up to $200 million in potential milestone payments. Acquired worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus with FDA Breakthrough Therapy designation.
  • Davis PolkminorOthers · 1 December 2025Davis Polk advised Mirum on $200 million private placement of common stock and pre-funded warrants to fund clinical development and pipeline expansion.
  • TakedacoreChannel Partner/ Reseller/ Distributor · 1 January 2024Takeda serves as commercial partner for LIVMARLI in Japan, handling regulatory approvals and commercialization. LIVMARLI was approved in Japan through partner Takeda for PFIC and Alagille syndrome.
  • Enthorin TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 1 January 2024Mirum licensed MRM-3379 (formerly ENT-3379), an orally available selective PDE4D inhibitor for Fragile X syndrome, from Enthorin Therapeutics. Mirum initiated BLOOM Phase 2 clinical study in December 2025.
  • PreventionGeneticsminorStrategic or Co-development Partner · 1 January 2024Partnership through Scout by Mirum program providing free genetic testing kits including 143-gene cholestasis panel, 66-gene early-onset bilateral cataracts panel, and PBD-ZSD testing.
  • Cincinnati Children's Hospital Medical CenterminorStrategic or Co-development Partner · 1 January 2024Partnership through Scout by Mirum program providing mass spectrometry testing for bile acid synthesis disorders and peroxisomal disorders at no cost to patients.
  • Oregon Health & Science UniversityminorStrategic or Co-development Partner · 1 January 2024Partnership through Scout by Mirum program for cerebrotendinous xanthomatosis (CTX) testing through OHSU Sterol Analysis Clinical Laboratory.
  • Kennedy Krieger InstituteminorStrategic or Co-development Partner · 1 January 2024Partnership through Scout by Mirum program for Smith-Lemli-Opitz syndrome (SLOS) testing providing biochemical test for cholesterol and 7/8-DHC intermediates.

Scale indicators10 records

Recent moves6 records

Expansion highlights3 records

Mirum Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Established rare-disease unit of AstraZeneca with multiple approved rare-disease therapies and global commercial reach. Comparable in commercial rare-disease infrastructure and orphan-drug pricing model.
  • Takeda Pharmaceutical: Global biopharma with a large rare disease franchise (post-Shire acquisition) and existing commercial partnership with Mirum in Japan. Operates broadly in rare GI/liver diseases; comparable in therapeutic area but at vastly greater scale.
  • Ipsen: Global specialty pharma with strong rare disease and hepatic portfolios. Overlaps with Mirum in liver and rare disease therapy categories but operates at meaningfully greater scale and portfolio breadth.

Direct peers

  • Alnylam Pharmaceuticals: Commercial-stage biopharmaceutical company focused on rare genetic diseases with multiple approved RNAi therapeutics. Comparable in scale, rare-disease focus, and reliance on specialty distribution and orphan-drug pricing economics.
  • BioMarin Pharmaceutical: Established rare-disease biopharma with a multi-product commercial portfolio of orphan drugs across multiple therapeutic areas. Most directly comparable to Mirum in business model: a focused rare-disease commercial engine with ongoing pipeline replenishment.
  • Recordati Rare Diseases: Specialty pharma division focused on rare diseases with global commercialization infrastructure. Comparable in rare-disease commercial model and emphasis on smaller patient populations with high unmet need.
  • Ultragenyx Pharmaceutical: Rare and ultra-rare disease biotech with multiple approved products and a similar specialty distribution model. Overlapping customer base (specialty prescribers, rare disease advocacy) and similar pipeline-driven growth narrative.

Emerging players

  • Intercept Pharmaceuticals: Liver-focused biopharma commercializing obeticholic acid for PBC. Comparable therapeutic focus on rare cholestatic liver disease and similar commercial model targeting hepatologists, though now under Alfasigma ownership.
  • SpringWorks Therapeutics: Commercial-stage rare disease biotech with focused launches in ultra-rare oncology and rare disorders. Comparable in company stage, rare-disease commercial motion, and reliance on single-asset growth narratives.
  • Genfit: Late-stage biotech focused on cholestatic and metabolic liver diseases, including PBC. Direct overlap with Mirum's volixibat program in primary biliary cholangitis — a head-to-head competitive threat in the IBAT/PBC space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Mirum Pharmaceuticals social profiles

Digital presence

Mirum Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mirum Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Mirum Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Mirum Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mirum Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mirum Pharmaceuticals

What does Mirum Pharmaceuticals do?

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases, primarily cholestatic liver diseases and other ultra-rare conditions. The company markets three FDA-approved medicines — LIVMARLI (maralixibat), CHOLBAM (cholic acid), and CTEXLI (chenodiol) — and has a pipeline of investigational therapies including volixibat, brelovitug, zilurgisertib, and MRM-3379 targeting high-unmet-need patient populations.

Is Mirum Pharmaceuticals a public or private company?

Mirum Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Mirum Pharmaceuticals founded?

Mirum Pharmaceuticals was founded in 2018. It employs 501 to 1,000 people.

Where is Mirum Pharmaceuticals based?

Mirum Pharmaceuticals is headquartered in Foster City, United States, in the North America region.

How does Mirum Pharmaceuticals make money?

Three revenue lines are on record. LIVMARLI (maralixibat) sales are the primary driver. The others are CHOLBAM/CTEXLI (bile acid medicines) and pipeline development and potential future product launches.

Who are Mirum Pharmaceuticals's main competitors?

Broad incumbents on record are Alexion (AstraZeneca Rare Disease), Takeda Pharmaceutical and Ipsen. Direct peers are Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Recordati Rare Diseases and Ultragenyx Pharmaceutical. Emerging players are Intercept Pharmaceuticals, SpringWorks Therapeutics and Genfit.

Does Mirum Pharmaceuticals have an API?

No public API is recorded for Mirum Pharmaceuticals.

What industry is Mirum Pharmaceuticals in?

Mirum Pharmaceuticals's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comMirum at Jefferies global healthcare conference: growth, launches aheadMirum Pharmaceuticals outlined its rare-disease portfolio at the Jefferies Global Healthcare Conference, guiding full-year revenue to $715–720 million. The company reported LIVMARLI's 69% growth and a $4 billion peak sales potential, with new launches expected in 2028. It also highlighted brelovitug's positive phase III data and ATEBRIOZ's U.S. launch.American Banking and Market NewsMirum Pharmaceuticals, Inc. $MIRM Holdings Boosted by Fisher Asset Management LLCFisher Asset Management raised its stake in Mirum Pharmaceuticals by 137.9% in Q3, acquiring 113,723 additional shares. Analysts have a consensus "Moderate Buy" rating with an average price target of $155.56. The company reported Q3 EPS of -$0.87, missing estimates, but revenue rose 39.6% year-over-year.American Banking and Market NewsCritical Contrast: Mirum Pharmaceuticals (NASDAQ:MIRM) versus Evogene (NASDAQ:EVGN)Mirum Pharmaceuticals and Evogene are compared on valuation, risk, ownership, and analyst ratings. Mirum has higher revenue ($670.78M vs $3.85M) but lower earnings, and analysts rate it more favorably with a 65.51% upside. Mirum beats Evogene on 10 of 15 factors.Investing.comMirum Pharmaceuticals CFO Eric Bjerkholt sells $978,092 sharesMirum Pharmaceuticals CFO Eric Bjerkholt sold 9,943 shares on September 14, 2026, for $978,092, to cover tax withholding from restricted stock unit vesting. The company reported Q3 2026 net product sales of $185.7 million, up 40% year-over-year, though EPS of -$0.87 missed estimates. Analysts raised price targets citing positive Phase 3 trial results.TradingViewMirum Pharmaceuticals Director Sold Shares Worth Over $1.3MMirum Pharmaceuticals director Laura Brege sold 14,167 shares in two transactions at weighted average prices of $94.05 and $94.74 per share, generating $1,334,655 in proceeds. After the sales, she directly owned 15,703 shares.Simply Wall StMirum Pharmaceuticals (MIRM) Phase 3 Win Sets Up FDA Plans, Is It Still 38% Below Fair Value?Mirum Pharmaceuticals' Phase 3 AZURE-4 trial of brelovitug for chronic hepatitis delta virus met its primary endpoint, supporting a planned U.S. FDA filing. The stock rose 8.49% over the past week, but remains 38% below the analyst consensus fair value of $153.43.Investing.comMirum Pharmaceuticals at Stifel 2026 Healthcare Conference: growth broadensMirum Pharmaceuticals outlined its business at the Stifel 2026 Healthcare Conference, citing four approved medicines and expected revenue of $715-720 million for 2024. The company expects negative cash flow in the second half of 2024 due to R&D spending, with a return to cash flow positivity in 2027. LIVMARLI remains the main growth engine, with strong patent protection extending to 2040-2043.TradingViewCitigroup maintains Mirum Pharmaceuticals at Buy, raises price target to $194 from $184Citigroup maintained Mirum Pharmaceuticals at Buy and raised its price target to $194 from $184, a 5.4% increase. The target implies an upside of 105.5% from the Nov 10 close of $94.42. Recent analyst price targets range from $140 to $202.Endpoints NewsMirum plans FDA submission for hepatitis D treatment as competition brewsMirum Pharmaceuticals plans an FDA submission for its hepatitis D treatment after the drug succeeded in the second of two pivotal trials. The company now faces competition in a growing market.YahooMirum's liver infection drug lowers virus levels in second late-stage studyMirum Pharmaceuticals reported that its hepatitis delta drug brelovitug reduced virus and normalized liver enzymes in 59% of patients after 24 weeks, versus none in the delayed-treatment group. The study enrolled 113 previously untreated patients, more than half with cirrhosis. The company expects a US approval application in the first half of 2027.